Details of Drug-Drug Interaction
| Drug General Information (ID: DDIBZ7OL8Y) | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Drug Name | Vedolizumab | Drug Info | Typhoid vaccine (live) | Drug Info | |||||
| Drug Type | Monoclonal antibody | Vaccine | |||||||
| Therapeutic Class | Selective Immunosuppressants | Vaccine | |||||||
| Mechanism of Vedolizumab-Typhoid vaccine (live) Interaction (Severity Level: Major) | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Antagonize the effect of vaccine/toxoid Click to Show/Hide Mechanism Graph | |||||||||
 |
|||||||||
| Drug Name | Vedolizumab | Typhoid vaccine (live) | |||||||
| Mechanism | Immunosuppressive effects | Vaccine or toxoid | |||||||
| Key Mechanism Factor 1 | |||||||||
| Factor Name | Vaccine/toxoid | ||||||||
| Factor Description | The beneficial effects of the vaccine/toxinoid may be reduced, leading to a diminished or suboptimal immune response. | ||||||||
| Mechanism Description |
|
||||||||
| Recommended Action | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Management | In general, live attenuated vaccines should not be used in patients receiving immunosuppressive therapy. Vaccination should be deferred until after such therapy is discontinued for at least 3 months in most cases, and longer following treatment with agents that have a prolonged elimination half-life. In patients who have recently been vaccinated, such therapy should not be initiated for at least 2 weeks. Vedolizumab labeling recommends that patients be brought up-to-date with all immunizations according to current immunization guidelines prior to initiating treatment. Live vaccines may be administered concurrently with vedolizumab only if the benefits outweigh the risks. | ||||||||